{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:32:25Z","timestamp":1769063545944,"version":"3.49.0"},"reference-count":0,"publisher":"Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediterr J Hematol Infect Dis"],"abstract":"<jats:p>Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality.\nMethods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study.\nResults: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p&lt;0.001) and had more comorbidities (p&lt;0.05). There were significantly more patients with low lymphocyte percentage (p&lt;0.001), thrombocytopenia (p&lt;0.001), and high CRP (p&lt;0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p&lt;0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality.\nConclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19.\nKeywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.<\/jats:p>","DOI":"10.4084\/mjhid.2022.074","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T10:59:39Z","timestamp":1667213979000},"page":"e2022074","source":"Crossref","is-referenced-by-count":6,"title":["IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY"],"prefix":"10.4084","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8657-1407","authenticated-orcid":false,"given":"\u0130brahim Halil","family":"A\u00e7ar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-2966","authenticated-orcid":false,"given":"Sebnem","family":"Izmir G\u00fcner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-3138","authenticated-orcid":false,"given":"Muzeyyen","family":"Aslaner Ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-7154","authenticated-orcid":false,"given":"Mesut","family":"Gocer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-8047","authenticated-orcid":false,"given":"Erman","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-2913","authenticated-orcid":false,"given":"Figen","family":"Atalay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7671-7628","authenticated-orcid":false,"given":"Gulden","family":"Sincan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-5955","authenticated-orcid":false,"given":"Aysun","family":"Senturk Yikilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4636-3590","authenticated-orcid":false,"given":"Omer","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-5100","authenticated-orcid":false,"given":"Idris","family":"Ince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-6162","authenticated-orcid":false,"given":"Emine","family":"Gulturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-6065","authenticated-orcid":false,"given":"Nazli","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0207-3505","authenticated-orcid":false,"given":"Ali","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-2286","authenticated-orcid":false,"given":"Yildiz","family":"Ipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-5673","authenticated-orcid":false,"given":"Birol","family":"Guvenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2554","published-online":{"date-parts":[[2022,10,29]]},"container-title":["Mediterranean Journal of Hematology and Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/mjhid.org\/index.php\/mjhid\/article\/download\/5054\/4245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mjhid.org\/index.php\/mjhid\/article\/download\/5054\/4246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mjhid.org\/index.php\/mjhid\/article\/download\/5054\/4245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T10:59:40Z","timestamp":1667213980000},"score":1,"resource":{"primary":{"URL":"https:\/\/mjhid.org\/index.php\/mjhid\/article\/view\/5054"}},"subtitle":["COVID-19 and hematologic malignancy"],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.4084\/mjhid.2022.074","relation":{},"ISSN":["2035-3006"],"issn-type":[{"value":"2035-3006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}